Positron-Emission Tomography With Vesicular Monoamine Transporter Ligand ([18F]-DTBZ) In Healthy Elderly And Young Subjects

Chang Gung Medical Foundation

Status and phase

Completed

Phase 2

Conditions

Healthy

Treatments

Drug: 18F-DTBZ AV-133

Study type

Interventional

Funder types

Other

Identifiers

NCT01838785

99-4149A

Details and patient eligibility

About

A total 25 healthy subjects will be included in this study. Subjects between 20 and 80 years of age may be eligible for this study. Candidates are screened with a medical history and physical examination, and blood test.

Full description

The primary objective of this protocol is to assess the possible age-dependent decline in striatal 18F-DTBZ uptake of healthy subjects.

This study is expected to be completed in a period of 2 years.

Enrollment

25 patients

Sex

All

Ages

20 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Male or female age 20 years to 80 years.
Subjects without significant neuropsychiatric disorder after evaluation by Neurologist.
Subjects who provide a written informed consent prior to study entry. If the subject is incapable of informed consent, the caregiver may consent on behalf of the subject (the subject must still confirm assent).

Exclusion criteria

Pregnancy and breast feeding.
Significant recent (within 6 months) history of neurological (including stroke and brain trauma) or psychiatric disorder.
Alcohol or substance abuse within last year.
Parkinson's disease or other brain degenerative disease (spinocerebellar ataxia, Wilson's disease, hydrocephalus, multiple infarction, history of severe head injury or intracranial operation.
Unable to stay still in the MRI or PET scanner for 30 minutes.